All Studies Meta Analysis Recent:

COVID-19 mortality among selective serotonin reuptake inhibitor users - Results from a nationwide cohort

Stauning et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2023.04.028

May 2023

Post
Facebook

Source PDF All Meta

Fluvoxamine

26th treatment shown to reduce risk in November 2021

^*, now known with p = 0.00014 from 21 studies, recognized in 3 countries.

Lower risk for mortality, hospitalization, progression, recovery, and cases.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,100+ studies for 60+ treatments. c19early.org

Retrospective 7,113 COVID+ SSRI users and 279,334 COVID+ non-SSRI users in Denmark, showing lower mortality with fluoxetine, without statistical significance, but higher mortality for other SSRIs.

Important missing comments or errors? Let us know.

risk of death, 57.7% lower, HR 0.42, p = 0.39, NNT 182, adjusted per study, odds ratio converted to relative risk, fluoxetine, multivariable, Cox proportional hazards.

risk of progression, 44.5% lower, HR 0.55, p = 0.30, adjusted per study, odds ratio converted to relative risk, fluoxetine, severe acute respiratory syndrome or death, multivariable, Cox proportional hazards.

risk of progression, 10.8% lower, HR 0.89, p = 0.84, adjusted per study, odds ratio converted to relative risk, fluoxetine, severe acute respiratory syndrome, multivariable, Cox proportional hazards.

risk of death, 31.6% higher, HR 1.32, p = 0.01, adjusted per study, odds ratio converted to relative risk, all SSRIs, multivariable, Cox proportional hazards.

risk of progression, 22.5% higher, HR 1.22, p < 0.001, adjusted per study, odds ratio converted to relative risk, all SSRIs, severe acute respiratory syndrome or death, multivariable, Cox proportional hazards.

risk of progression, 6.9% higher, HR 1.07, p = 0.40, adjusted per study, odds ratio converted to relative risk, all SSRIs, severe acute respiratory syndrome, multivariable, Cox proportional hazards.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Stauning et al., 5 May 2023, retrospective, Denmark, peer-reviewed, mean age 50.4, 4 authors, study period 26 February, 2020 - 5 October, 2021. Contact: marius.ahm.stauning@regionh.dk.

This Paper Fluvoxamine All

COVID-19 mortality among selective serotonin reuptake inhibitor users—results from a nationwide cohort

M.D Marius Ahm Stauning, Dogukan Jesper Gür, Christian Torp-Pedersen, Jens Tingleff

Clinical Microbiology and Infection, doi:10.1016/j.cmi.2023.04.028

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest CTP has previously received research grants from Novo Nordisk and Bayer AG not related to the current study. Remaining authors declare no conflict of interest. Author contributions Writing

References

Albayrak, Hashimoto, Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders, Advances in Experimental Medicine and Biology, doi:10.1007/978-3-319-50174-1_11

Baadsgaard, Quitzau, Danish registers on personal income and transfer payments, Scandinavian Journal of Public Health, doi:10.1177/1403494811405098

Calusic, Marcec, Luksa, Jurkovic, Kovac et al., Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls, British Journal of Clinical Pharmacology, doi:10.1111/bcp.15126

Core, R: A Language and Environment for Statistical Computing. Version 3.4.1 "Single Candle" Copyright (C), The R Foundation for Statistical Computing

Fico, Isayeva, Prisco, Oliva, Solè et al., Psychotropic drug repurposing for COVID-19: a Systematic Review and Meta-Analysis, European Neuropsychopharmacology, doi:10.1016/j.euroneuro.2022.10.004

Firouzabadi, Kheshti, Abdollahifard, Taherifard, Kheshti, The effect of selective J o u r n a l P r e -p r o o f serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis, Health Science Reports, doi:10.1002/hsr2.892

Fosbøl, Gislason, Jacobsen, Abildstrom, Hansen et al., The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: A nationwide study on 4.6 million people, Pharmacoepidemiology and Drug Safety, doi:10.1002/pds.1592

Frank, Epidemiology, When an entire country is a cohort, Science, doi:10.1126/SCIENCE.287.5462.2398

Hamer, Kivimäki, Gale, Batty, Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK, Brain, Behavior, and Immunity, doi:10.1016/J.BBI.2020.05.059

Hannestad, Dellagioia, Bloch, The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis, Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, doi:10.1038/NPP.2011.132

Hashimoto, Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor, European Archives of Psychiatry and Clinical Neuroscience, doi:10.1007/S00406-020-01231-X

Hashimoto, Suzuki, Hashimoto, Mechanisms of action of fluvoxamine for COVID-19: a historical review, Molecular Psychiatry, doi:10.1038/s41380-021-01432-3

Hoertel, Sánchez-Rico, Kornhuber, Gulbins, Reiersen et al., Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19, Journal of Clinical Medicine, doi:10.3390/jcm11195882

Hoertel, Sánchez-Rico, Vernet, Beeker, Jannot et al., Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Molecular Psychiatry, doi:10.1038/s41380-021-01021-4

Jensen, Rasmussen, Danish education registers, Scandinavian Journal of Public Health, doi:10.1177/1403494810394715

Kildemoes, Sørensen, Hallas, The Danish National Prescription Registry, Scandinavian Journal of Public Health, doi:10.1177/1403494810394717

Kuswardhani, Henrina, Pranata, Lim, Lawrensia et al., Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis, Diabetes & Metabolic Syndrome, doi:10.1016/J.DSX.2020.10.022

Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients with Symptomatic COVID-19: A Randomized Clinical Trial, JAMA -Journal of the American Medical Association, doi:10.1001/jama.2020.22760

Nyirenda, Sofroniou, Toews, Mikolajewska, Lehane et al., Fluvoxamine for the treatment of COVID-19, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD015391

Oskotsky, Marić, Tang, Oskotsky, Wong et al., Mortality Risk among Patients with COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants, JAMA Network Open, doi:10.1001/jamanetworkopen.2021.33090

Pedersen, The Danish Civil Registration System, Scandinavian Journal of Public Health, doi:10.1177/1403494810387965

Quan, Sundararajan, Halfon, Fong, Burnand et al., Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data, Medical Care, doi:10.1097/01.MLR.0000182534.19832.83

Rauchman, Mendelson, Rauchman, Kasselman, Pinkhasov et al., Ongoing use of SSRIs does not alter outcome in hospitalized COVID-19 patients: A retrospective analysis, Journal of Clinical Medicine, doi:10.3390/jcm11010070

Reis, Moreira-Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, The Lancet Global Health, doi:10.1016/S2214-109X(21)00448-4

Schmidt, Schmidt, Adelborg, Sundbøll, Laugesen et al., The Danish health care system and epidemiological research: from health care contacts to database records, Clinical Epidemiology, doi:10.2147/CLEP.S179083

Schmidt, Schmidt, Sandegaard, Ehrenstein, Pedersen et al., The Danish National Patient Registry: a review of content, data quality, and research potential, Clinical Epidemiology, doi:10.2147/CLEP.S91125

Seftel, Boulware, Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19, Open Forum Infectious Diseases, doi:10.1093/ofid/ofab050

Vai, Mazza, Marisa, Beezhold, Kärkkäinen et al., Joint European policy on the COVID-19 risks for people with mental disorders: An umbrella review and evidence-and consensus-based recommendations for mental and public health, European Psychiatry, doi:10.1192/J.EURPSY.2022.2307

Voldstedlund, Haarh, Mølbak, The danish microbiology database (MIBA), Eurosurveillance, doi:10.2807/1560-7917.ES2014.19.1.20667/CITE/PLAINTEXT

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0